Oncology

In this clip from the Hematology/Oncology Pharmacy Association, Alison Duffy, PharmD, BCOP, from the University of Maryland Greenbaum Comprehensive Cancer Center, shares important considerations in treating Chronic Lymphocytic Leukemia in patients.

The oncology drug pipeline has experienced rapid growth over the past decade, driven by innovation in cell therapies, immunotherapy, and precision medicine, according to a specialty pipeline update presentation at the Asembia Specialty Pharmacy Summit 2019.

Mouthwash containing diphenhydramine, lidocaine, and antacids found to significantly reduce pain from oral mucositis in patients with head and neck cancer administered chemotherapy.

Amber Draper, PharmD, BCOP, clinical pharmacist at Winship Cancer Institute discussed how biomarkers are used to make informed decisions in colorectal cancer treatment.

Alison Duffy, PharmD, BCOP, from UM Greenebaum Comprehensive Cancer Center, talks about some of the emerging agents in the chronic lymphocytic leukemia treatment landscape.

Lisa Holle, PharmD, BCOP, FHOPA, associate clinical professor at the University of Connecticut discusses the evolving role of genomics in the treatment of prostate cancer.

Investigators used a CRISPR technique to expose weaknesses in the acute myeloid leukemia enzyme that many drugs target.

The combination of selinexor and 4-OHT may be able to prevent endocrine resistance in hormone-responsive breast cancer by rewiring gene pathways.

This is the first indication for pembrolizumab (Keytruda, Merck) in advanced renal cell carcinoma.

What considerations should pharmacists keep in mind when treating patients with chronic lymphocytic leukemia?

Bernard Marini, PharmD, BCOP, gives an overview of selecting the most effective, safest, and most cost-effective acute myeloid leukemia treatments for patients.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Study finds that surgery was associated with a 44% increased chance of survival in patients with breast cancer, assuming the majority also had systemic treatment.

Lisa Holle, PharmD, BCOP, FHOPA, associate clinical professor at the University of Connecticut discusses key trials in prostate cancer research.

Amber Draper, PharmD, BCOP, clinical pharmacist at Winship Cancer Institute, discussed the recent updates to the American Cancer Society's screening guidelines for colorectal cancer.

Alison Duffy, PharmD, BCOP, from UM Greenebaum Comprehensive Cancer Center, provides an overview of the evolving treatment paradigm for chronic lymphocytic leukemia.

Study finds a dramatic difference between guidelines for tests such as mammograms and colon cancer screenings between the United Kingdom and the United States.

Alison Duffy, PharmD, BCOP, from UM Greenebaum Comprehensive Cancer Center, discusses the importance of the pharmacist's role in the management of chronic lymphocytic leukemia treatments.

Amber Draper, PharmD, BCOP, clinical pharmacist at Winship Cancer Institute, explains how pharmacists can counsel patients about risk factors for colorectal cancer and reduction strategies.

Amber Draper, PharmD, BCOP, clinical pharmacist at Winship Cancer Institute, discussed emerging trends in oncology care.

Lisa Holle, PharmD, BCOP, FHOPA, associate clinical professor at the University of Connecticut, explains which patient populations would best benefit from either apalutamide versus enzalutamide in the treatment of non-metastatic prostate cancer.

Updated clinical practice guidelines from the National Comprehensive Cancer Network (NCCN) review patient selection for the use of agents such as ibrutinib for the treatment of chronic lymphocytic leukemia.

Enfortumab vedotin is being investigated for the treatment of locally advanced or metastatic urothelial cancer following both platinum-containing chemotherapy and a PD-1 or PD-L1 inhibitor.

The indication’s expansion for palbociclib to include male patients is based upon data from postmarketing reports and electronic health records showing that the safety profile for men treated with the drug is consistent with the safety profile in women treated with this medication.

The daratumumab (Darzalex) combination therapy would be the first for use in the frontline setting for transplant-eligible patients with multiple myeloma.

Although lung cancer screenings are covered at no cost by most insurers, state Medicaid programs are not required to offer coverage for this service.

In this clip, Jamie Fritz, RPh, Retail Pharmacy Manager at Compass Oncology, explains the treatment support kit committee of the National Community Oncology Dispensing Association and how these kits are designed for each specific patient.

Top news of the day from across the health care industry.